Exopolysaccharides From Lactobacillus delbrueckii subsp. bulgaricus OLL1073R‐1 Enhance Macrophage Bactericidal Activity Through IL‐12‐Dependent Macrophage–NK Cell Crosstalk
Microbiology and Immunology · 2026-11 · 70 (11) · 566-572
DOI: 10.1111/1348-0421.70090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology and Immunology, online erschienen am 14.09.2026. Verfasst von Chikara Kohda und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Showa Medical University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Macrophages, Lactobacillus delbrueckii, Interleukin-12, Killer Cells, Natural. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Meiji Holdings Co. Ltd..
Abstract (Originalsprache)
Exopolysaccharides (EPS) produced by Lactobacillus delbrueckii subsp. bulgaricus OLL1073R‐1 have been reported to exert immunomodulatory effects, primarily in antiviral responses; however, their role in antibacterial host defense remains unclear. Here, we investigated whether EPS enhance macrophage‐mediated killing of Streptococcus pyogenes , a facultative intracellular pathogen, using an in vitro co‐culture system with NK‐like cells. EPS alone did not enhance the intracellular bactericidal activity of macrophages. In contrast, EPS significantly increased bacterial killing when macrophages were co‐cultured with NK‐like cells. Mechanistically, EPS induced interleukin (IL)−12 expression in macrophages, while interferon (IFN)‐γ production was not detected when macrophages or NK‐like cells were cultured separately, but was significantly induced in the co‐culture system. Neutralization of IL‐12 or IFN‐γ significantly abrogated the EPS‐mediated enhancement of bactericidal activity, indicating that both cytokines are required for this effect. These findings support a model in which EPS stimulate macrophages to produce IL‐12, leading to NK cell activation and subsequent IFN‐γ–dependent enhancement of macrophage bactericidal function. Our results reveal a previously uncharacterized role of probiotic‐derived EPS in promoting antibacterial immunity through macrophage–NK cell crosstalk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Showa Medical University School of Medicine, Tokyo, Japan.
- Division of Nephrology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan.
- Wellness Science Labs, Meiji Holdings Co., Ltd., Tokyo, Hachioji, Japan.
- Department of Oral Microbiology and Immunology, Showa Medical University School of Dentistry, Tokyo, Shinagawa, Japan.
ORCID-Profile: Chikara Kohda, Hiroki Ishikawa, Toshihiro Sashihara, Hirotaka Kuwata, Masayuki Iyoda
Förderung
- Meiji Holdings Co. Ltd.
Zitieren
APA
Kohda, C., Ishikawa, H., Kuno, Y., Matsuzaka, Y., Kono, H., Sashihara, T., Kuwata, H., & Iyoda, M. (2026). Exopolysaccharides From Lactobacillus delbrueckii subsp. bulgaricus OLL1073R‐1 Enhance Macrophage Bactericidal Activity Through IL‐12‐Dependent Macrophage–NK Cell Crosstalk. Microbiology and Immunology, 70(11), 566-572. https://doi.org/10.1111/1348-0421.70090
Vancouver
Kohda C, Ishikawa H, Kuno Y, Matsuzaka Y, Kono H, Sashihara T, et al. Exopolysaccharides From Lactobacillus delbrueckii subsp. bulgaricus OLL1073R‐1 Enhance Macrophage Bactericidal Activity Through IL‐12‐Dependent Macrophage–NK Cell Crosstalk. Microbiology and Immunology. 2026;70(11):566-572. doi:10.1111/1348-0421.70090
BibTeX
@article{Kohda2026,
author = {Kohda, Chikara and Ishikawa, Hiroki and Kuno, Yoshihiro and Matsuzaka, Yasunari and Kono, Hiroki and Sashihara, Toshihiro and Kuwata, Hirotaka and Iyoda, Masayuki},
title = {Exopolysaccharides From Lactobacillus delbrueckii subsp. bulgaricus OLL1073R‐1 Enhance Macrophage Bactericidal Activity Through IL‐12‐Dependent Macrophage–NK Cell Crosstalk},
journal = {Microbiology and Immunology},
year = {2026},
volume = {70},
number = {11},
pages = {566--572},
doi = {10.1111/1348-0421.70090}
}
EUVIMED